Rego Brianna
Department of History, Stanford University, Stanford, California 94305-2024, USA.
Isis. 2009 Sep;100(3):453-84. doi: 10.1086/644613.
The first scientific paper on polonium-210 in tobacco was published in 1964, and in the following decades there would be more research linking radioisotopes in cigarettes with lung cancer in smokers. While external scientists worked to determine whether polonium could be a cause of lung cancer, industry scientists silently pursued similar work with the goal of protecting business interests should the polonium problem ever become public. Despite forty years of research suggesting that polonium is a leading carcinogen in tobacco, the manufacturers have not made a definitive move to reduce the concentration of radioactive isotopes in cigarettes. The polonium story therefore presents yet another chapter in the long tradition of industry use of science and scientific authority in an effort to thwart disease prevention. The impressive extent to which tobacco manufacturers understood the hazards of polonium and the high executive level at which the problem and potential solutions were discussed within the industry are exposed here by means of internal documents made available through litigation.
关于烟草中钋 - 210的第一篇科学论文于1964年发表,在接下来的几十年里,会有更多研究将香烟中的放射性同位素与吸烟者的肺癌联系起来。当外部科学家致力于确定钋是否可能是肺癌的病因时,行业科学家则在默默开展类似工作,目的是在钋问题一旦公开时保护商业利益。尽管四十年的研究表明钋是烟草中的主要致癌物,但制造商并未采取明确行动来降低香烟中放射性同位素的浓度。因此,钋的故事展现了行业利用科学和科学权威以阻碍疾病预防这一悠久传统中的又一章。通过诉讼获得的内部文件揭示了烟草制造商对钋危害的了解程度之深,以及该问题和潜在解决方案在行业内讨论所达到的高管层面。